Aflatoxin M1 in the urine of non-carriers and chronic carriers of hepatitis B virus in Maringa, Brazil

Authors

  • Marcel Padovani Giolo State University of Maringá; Department of Basic Health Sciences; Laboratory of Toxicology
  • Christiane Minervino de Oliveira State University of Maringá; Department of Basic Health Sciences; Laboratory of Toxicology
  • Dennis Armando Bertolini State University of Maringá; Department of Clinical Analysis and Biomedicine; Laboratory of Immunology
  • Maria Valdrinez Campana Lonardoni State University of Maringá; Department of Clinical Analysis and Biomedicine; Laboratory of Immunology
  • Matheus Sampaio Gouveia State University of Londrina; Department of Chemistry; Laboratory of Analytical Chemistry
  • Daisy Pontes Netto State University of Londrina; Department of Preventive Veterinary Medicine; Laboratory of Toxicology
  • Suzana Lucy Nixdorf State University of Londrina; Department of Chemistry; Laboratory of Analytical Chemistry
  • Miguel Machinski Junior State University of Maringá; Department of Basic Health Sciences; Laboratory of Toxicology

DOI:

https://doi.org/10.1590/S1984-82502012000300011

Keywords:

Aflatoxins, Biomarkers, Hepatitis B, Hepatocellular carcinoma, Urina^i1^sanálise toxicológ, Epidemiology

Abstract

Exposure to aflatoxins (AFs) in the diet may favour the development of hepatocellular carcinoma (HCC) and the acute exacerbation of hepatitis in chronic hepatitis B virus (HBV) carriers. Measurement of biomarkers such as aflatoxin M1 (AFM1), a metabolite of aflatoxin B1 (AFB1), in urine allows for the assessment of populations exposed to aflatoxins. The aim of this study was to investigate the occurrence of aflatoxin M1 in the urine of HBV carrier and non-carrier patients. One group included 43 randomly selected HBV carriers treated at two hospitals in the city of Maringa, Brazil, from March to June 2008. Control group consisted of 29 healthy adult volunteers with anti-HBs positive and HBsAg negative test results. Detection of AFM1 was performed by fluorescence using high performance liquid chromatography (HPLC) and post-column derivation with the Kobra Cell®. Of the 72 samples analysed, 05/29 (17.2%) AFM1 positive samples were from HBV non-carriers, and 16/43 (37.2%) of samples were from chronic HBV carriers. This study showed AFM1 in the urine of the two surveyed population. However, there is evidence that the chronic HBV carriers have a higher risk of developing HCC due to additive interaction between AFs and HBV.

Downloads

Download data is not yet available.

Downloads

Published

2012-09-01

Issue

Section

Articles

How to Cite

Aflatoxin M1 in the urine of non-carriers and chronic carriers of hepatitis B virus in Maringa, Brazil. (2012). Brazilian Journal of Pharmaceutical Sciences, 48(3), 447-452. https://doi.org/10.1590/S1984-82502012000300011